A Study of Evacetrapib in Healthy Participants



Status:Completed
Conditions:Healthy Studies
Therapuetic Areas:Other
Healthy:No
Age Range:18 - 65
Updated:10/5/2018
Start Date:December 2012
End Date:February 2013

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects

The purpose of this study is to determine whether concentrations of the study drug
(evacetrapib) in the blood stream is the same or is different when the person is also taking
gemfibrozil (a drug used to lower lipid levels). Each participant will receive gemfibrozil
alone, evacetrapib alone, and both drugs in combination. There is no washout period between
doses. The safety of both of the study drugs given together will be evaluated. Information
about any side effects that may have occurred will also be collected. This study will last
approximately 36 days.


Inclusion Criteria:

- Healthy participants as determined by medical history and physical examination

- Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2)

Exclusion Criteria:

- Have known allergies to evacetrapib and gemfibrozil, related compounds or any
components of the formulation

- Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the
investigator, increases the risks associated with participating in the study

- Regularly use known drugs of abuse and/or show positive findings on urinary drug
screening

- Currently smoke cigarettes or use tobacco or nicotine substitutes
We found this trial at
1
site
Clinical Trial Facility in Daytona Beach Florida
Daytona Beach, Florida 32117
?
mi
from
Daytona Beach, FL
Click here to add this to my saved trials